A practical reference on intranasal delivery: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-24 and is reviewed periodically as new material appears.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
| Property | Value | Notes |
|---|---|---|
| Purity assay | RP-HPLC, UV 214 nm | Typical research grade 95 percent or higher |
| Mass confirmation | ESI-MS or MALDI-TOF | Compared with theoretical value |
| Main degradation route | Methionine oxidation | Sulfoxide formation in solution |
| Powder storage | -20 °C, desiccated | Amber vial, minimal headspace |
| Working solution | Sterile water or saline | Prepare fresh; avoid repeated thawing |
Dissolution is normally performed in water, phosphate-buffered saline, or normal saline, since the peptide is freely soluble in aqueous media and is rarely handled with strong organic solvents. Solution pH should be kept near neutral, because extreme acidity or alkalinity accelerates backbone hydrolysis and encourages oxidation of the methionine side chain. Once dissolved, the material is less stable than the dry powder and is commonly divided into single-use portions and frozen. Buffers containing primary amines, such as Tris, are often avoided because of possible side reactions.
Purity assessment relies mainly on reversed-phase high-performance liquid chromatography, which separates the target heptapeptide from truncated sequences, deletion analogues, and oxidised forms. Mass spectrometry, usually coupled to liquid chromatography, confirms identity through the expected molecular ion and reveals modifications such as methionine sulfoxide formation. Amino acid analysis can verify composition, and tandem mass spectrometry supports sequence confirmation. Ultraviolet detection near 254 to 280 nanometres is convenient because the phenylalanine and histidine residues absorb in that region. Nuclear magnetic resonance is rarely used for routine release testing.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
== Biosynthesis == (Z)-9-Tricosene is biosynthesized in house flies from nervonic acid. The acid is converted into the acyl-CoA derivative and then reduced to the aldehyde (Z)-15-tetracosenal. Through a decarboxylation reaction, the aldehyde is converted to (Z)-9-tricosene. The process is mediated by a cytochrome P450 enzyme and requires oxygen (O2) and nicotinamide adenine dinucleotide phosphate (NADPH).
== Interactions == A combination of ACE inhibitor with other drugs may increase effects of these drugs, but also the risk of adverse effects. Commonly reported adverse effects of drug combination with ACE inhibitor are acute renal failure, hypotension, and hyperkalemia. Drugs interacting with ACE inhibitor should be prescribed with caution. Special attention should be given to combinations of ACE inhibitor with diuretics (especially potassium-sparing diuretics), NSAIDs, anticoagulants, cyclosporine, DPP-4 inhibitors, and potassium supplements Angiotensin II receptor antagonists (ARBs) should not be used with ACE inhibitors. Dual RAAS inhibitor therapy (ACE inhbitors, ARBs, direct renin inhibitors, or mineralocorticoid receptor antagonists) has been found to significantly increase the risk of developing kidney damage and hyperkalemia. Potassium supplementation should be used with caution and under medical supervision owing to the hyperkalemic effect of ACE inhibitors. Concomitant use with cyclooxygenase inhibitors tends to decrease ACE inhibitor's hypotensive effect.
In a prospective study of community-dwelling people 60–90 years of age, in 1993, of unimmunized people, 23% of people who smoked had clinical influenza compared with 6% of people who did not smoke. Smoking may substantially contribute to the growth of influenza epidemics affecting the entire population.
{\displaystyle {\frac {[\mathrm {cyt~c_{red}} ]}{[\mathrm {cyt~c_{ox}} ]}}=\left({\frac {[\mathrm {NADH} ]}{[\mathrm {NAD} ]^{+}}}\right)^{\frac {1}{2}}\left({\frac {[\mathrm {ADP} ][\mathrm {P_{i}} ]}{[\mathrm {ATP} ]}}\right)K_{\mathrm {eq} }}
=== Familia GT-X, GT-A, GT-R, GT-Ae === For Group A rallying, Mazda made two main homologation models. The JDM GT-X model was released in 1990 and featured four-wheel drive, viscous limited-slip differentials and a turbocharged 1.8 L BPT engine which produced 185 PS (136 kW; 182 hp). Mazda also Produced 300 GT-A variants to celebrate the launch of the BG Familia GT-X and its rally debut. These were stripped of most luxuries and delivered with Mazdaspeed Torsen rear differential, short ratio gearbox, roll cage, harnesses, grille mounted fog lights. A graphics pack was also available. In Europe, the engine of the GT-X model was detuned to produce 166 PS (122 kW; 164 hp). The GT-R model was released in 1992, produced for around 5,000 units. The GT-R featuring a number of enhancements over the GT-X model: an aggressive front bumper, grille and bonnet vents, updated rear bumper, wheel flares, stiffer suspension and anti-roll bars with thicker cross members, and homologated five-stud wheel hubs with larger brakes. The interior was fitted with leather and faux suede seats, and had the option of replacing the cupholder with a 3-gauge cluster. In addition, the GT-R has stronger connecting rods and pistons, larger oil squirters, larger nose crank, larger oil cooler, sodium filled valves, a baffled inlet manifold, larger injectors, removed boost cut, front-mounted intercooler, and an IHI VJ-23 ball bearing water-cooled turbocharger. Power was increased to 210 PS (154 kW; 207 hp).
Sources: en.wikipedia.org
Since nitrogen bubbles are generated within each cell, the same disruptive force is applied uniformly throughout the sample, thus ensuring unusual uniformity in the product. Cell-free homogenates can be produced. The technique is used to homogenize cells and tissues, release intact organelles, prepare cell membranes, release labile biochemicals, and produce uniform and repeatable homogenates without subjecting the sample to extreme chemical or physical stress. The method is particularly well suited for treating mammalian and other membrane-bound cells. It has also been used successfully for treating plant cells, for releasing virus from fertilized eggs and for treating fragile bacteria. It is not recommended for untreated bacterial cells. Yeast, fungus, spores and other materials with tough cell walls do not respond well to this method.
==== Distribution ==== DMT easily crosses the blood–brain barrier. Studies on the llipophilicity of DMT have been contradictory – most studies find DMT to be either lipophilic or slightly lipophilic, but a 2023 study found it to be lipophobic. Several studies have described active transport and accumulation of DMT into rat and dog brains following peripheral administration. Similar active transport and accumulation processes likely occur in human brains and may concentrate DMT in brain by several-fold or more (relatively to blood), resulting in local concentrations in the micromolar or higher range. Such concentrations would be commensurate with serotonin brain tissue concentrations, which have been consistently determined to be in the 1.5–4 μmol/L range. The plasma protein binding of DMT is low at approximately 30%.
== Clinical considerations == Deficiency in human tRNA methylthiotransferase eMtaB has been shown to be responsible for abnormal insulin synthesis and predisposition to type 2 diabetes. Mutations in human GTP cyclase MoaA has been reported to lead to molybdenum cofactor deficiency, a usually fatal disease accompanied by severe neurological symptoms. Mutations in human wybutosine-tRNA modifying enzyme Tyw1 promotes retrovirus infection. Alterations in human tRNA-modifying enzyme Elp3 results in progression into amyotrophic lateral sclerosis (ALS). Mutations in human antiviral RSAD1 has been shown to be associated with congenital heart disease. Mutations in human sulfurtransferase LipA has been implicated in glycine encephalopathy, pyruvate dehydrogenase and lipoic acid synthetase deficiency. Mutations in human methylthiotransferase MiaB are related to impaired cardiac and respiratory functions.
Adversarial robustness is often associated with security. Researchers demonstrated that an audio signal could be imperceptibly modified so that speech-to-text systems transcribe it to any message the attacker chooses. Network intrusion and malware detection systems also must be adversarially robust since attackers may design their attacks to fool detectors. Models that represent objectives (reward models) must also be adversarially robust. For example, a reward model might estimate how helpful a text response is and a language model might be trained to maximize this score. Researchers have shown that if a language model is trained for long enough, it will leverage the vulnerabilities of the reward model to achieve a better score and perform worse on the intended task. This issue can be addressed by improving the adversarial robustness of the reward model. More generally, any AI system used to evaluate another AI system must be adversarially robust. This could include monitoring tools, since they could also potentially be tampered with to produce a higher reward. Large language models (LLMs) can be vulnerable to prompt injection and model stealing, and may be used to generate misinformation. Prompt injection involves embedding instructions into prompts in order to bypass safety measures. Some approaches against prompt injection use customizable policies and rules to analyze inputs and outputs, ensuring that potentially problematic interactions are filtered or mitigated.
== Interactions == No pharmacokinetic interactions with doxorubicin were observed in studies. Being a monoclonal antibody, olaratumab is neither metabolised by cytochrome P450 liver enzymes nor transported by transmembrane pumps, and is thus not expected to interact relevantly with other drugs.
Sources: en.wikipedia.org
==== India ==== Recent economic growth has led to development of new categories of alcohol in India. Cider is one such category. New product launches are seen in almost all metropolitan cities. Also a filtered non-alcoholic carbonated apple juice called "Appy Fizz" was introduced by Parle in India in 2005 and it became an instant hit. Recently, they have decided to push the brand beyond the ₹10 billion mark ($97.5 million).
In later years, Wenger's training regime has come under criticism, given his squad's poor injury record. From 2004–05 to 2014–15, Arsenal's players lost 13,161 days through injury, the most in the Premier League, and significantly more than Chelsea in second (7,217). In 2014, Wenger acquired the help of fitness coach Shad Forsythe to solve the problem; statistics revealed a year later that Arsenal's average injury length dropped more than 25% in Forsythe's first season.
== All-Star Games == Prior to the 2021 reorganization of the minor leagues, each of the active Double-A leagues held its own midseason All-Star Game. From 1991 to 2002, the three combined to hold the Double-A All-Star Game between teams of American League-affiliated All-Stars and National League-affiliated All-Stars. After the start of the 2021 minor league season was delayed by a month, team schedules were released without a break for an all-star game.
In biochemistry, flavin adenine dinucleotide (FAD) is a redox-active coenzyme associated with various proteins, which is involved with several enzymatic reactions in metabolism. A flavoprotein is a protein that contains a flavin group, which may be in the form of FAD or flavin mononucleotide (FMN). Many flavoproteins are known: components of the succinate dehydrogenase complex, α-ketoglutarate dehydrogenase, and a component of the pyruvate dehydrogenase complex. FAD exists in two common oxidation states, the fully oxidized form (FAD) and the fully reduced, dihydrogenated form, FADH2. Other oxidation states also exist, including the N-oxide and semiquinone states. FAD, in its fully oxidized form, accepts two electrons and two protons to become FADH2. The semiquinone (FADH·) can be formed by either reduction of FAD or oxidation of FADH2 by accepting or donating one electron and one proton, respectively. Some proteins, however, generate and maintain a super oxidized form of the flavin cofactor, the flavin-N(5)-oxide.
=== Genes are commonly interrupted by introns that must be removed by RNA splicing === Analysis of mature eukaryotic messenger RNA molecules showed that they are often much smaller than the DNA sequences that encode them. The genes were shown to be discontinuous, composed of sequences that are not present in the final mature RNA (introns), located between sequences that are retained in the mature RNA (exons). Introns were shown to be removed after transcription through a process termed RNA splicing. Splicing of RNA transcripts requires a highly precise and coordinated sequence of molecular events, consisting of (a) definition of boundaries between exons and introns, (b) RNA strand cleavage at exactly those sites, and (c) covalent linking (ligation) of the RNA exons in the correct order. The discovery of discontinuous genes and RNA splicing was entirely unexpected by the community of RNA biologists, and stands as one of the most shocking findings in molecular biology research.
Sources: en.wikipedia.org
Reversed-phase HPLC gives the main purity figure, most often with UV detection near 214 nanometres. Mass spectrometry then confirms the molecular mass. Together the two methods distinguish a correct sequence from a closely related impurity.
The main chemical risks are methionine oxidation and backbone hydrolysis in solution. Moisture and repeated temperature cycling accelerate both processes. Dry powder held cold and desiccated is considerably more stable than any reconstituted preparation.
It holds a medicine registration in Russia, where it has been used clinically for decades. In most other countries it is treated as a research chemical. That split explains the uneven distribution of clinical literature.
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.